+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rytary

  • PDF Icon

    Report

  • 14 Pages
  • June 2018
  • Region: Global
  • Pharma Intelligence
  • ID: 4775093
Drug Overview
Rytary (Impax Laboratories) is a novel oral capsule formulation of carbidopa and levodopa that contains both an immediate-release and a sustained-release levodopa component. Rytary is dosed three times daily, although its pharmacokinetic profile allows for smoother levodopa levels and consequently fewer motor fluctuations than conventional, immediate-release carbidopa + levodopa.

Rytary was finally approved by the US Food and Drug Administration in January 2015, despite over three years of regulatory scrutiny. Impax’s first submission in December 2011 resulted in a complete response letter requiring a re-inspection of its manufacturing facility. In the meantime, Impax’s former development partner GlaxoSmithKline terminated their agreement, leaving Impax to conclude the regulatory process and commercialize the product by itself.

Table of Contents

OVERVIEW
Drug Overview
Product Profiles
Rytary : Parkinson's disease
LIST OF FIGURES
Figure 1: Rytary for Parkinson’s disease – SWOT analysis
Figure 2: The authors drug assessment summary of Rytary for Parkinson’s disease
Figure 3: The authors drug assessment summary of Rytary for Parkinson’s disease
Figure 4: Rytary sales for Parkinson’s disease in the US, 2016–25
LIST OF TABLES
Table 1: Rytary drug profile
Table 2: Rytary pivotal trial data in Parkinson’s disease
Table 3: Rytary sales for Parkinson’s disease in the US ($m), 2016–25